Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Christians, Arne ^a   Hartmann, Christian ^e   Benner, Axel ^a   Meyer, Jochen ^a   von Deimling, Andreas ^a,b   Weller, Michael ^c,d   Wick, Wolfgang ^a,b,d   Weiler, Markus ^a,b,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PRIMER DNA; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; METHYLATION SPECIFIC MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; MGMT GENE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PYROSEQUENCING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SURVIVAL PREDICTION; TUMOR GENE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DNA SEQUENCE; EVALUATION; GENETIC PROCEDURES; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METHODOLOGY; NUCLEIC ACID AMPLIFICATION; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL MODEL;

DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA PRIMERS; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LIKELIHOOD FUNCTIONS; MOLECULAR PROBE TECHNIQUES; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 84863413030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033449     Document Type: Article

References (38)

1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
2. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354.
3. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, et al. (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938.
4. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, et al. (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199.
5. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, et al. (2010) Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 77: 670-676.
6. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, et al. (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27: 5743-5750.
7. Pegg AE, (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462: 83-100.
8. Karran P, Bignami M, (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839.
9. Gerson SL, (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307.
10. Preusser M, (2009) MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 24: 511-518.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB, (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821-9826.
12. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, et al. (2008) Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10: 332-337.
13. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, et al. (2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33: e128.
14. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89: 1827-1831.
15. Xiong Z, Laird PW, (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534.
16. Ronaghi M, Uhlen M, Nyren P, (1998) A sequencing method based on real-time pyrophosphate. Science 281: 363-365.
17. El-Maarri O, Herbiniaux U, Walter J, Oldenburg J, (2002) A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Res 30: e25.
18. Tanaka S, Kobayashi I, Utsuki S, Oka H, Fujii K, et al. (2003) O6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 103: 67-72.
19. Anda T, Shabani HK, Tsunoda K, Tokunaga Y, Kaminogo M, et al. (2003) Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 25: 241-248.
20. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J, (2008) Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 115: 249-259.
21. Preuss I, Eberhagen I, Haas S, Eibl RH, Kaufmann M, et al. (1995) O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer 61: 321-326.
22. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39-51.
23. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, et al. (2010) Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 12: 274-282.
24. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, et al. (1997) Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17: 5612-5619.
25. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, et al. (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22: 8835-8844.
26. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, et al. (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9: 368-381.
27. Everhard S, Tost J, El Abdalaoui H, Criniere E, Busato F, et al. (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11: 348-356.
28. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, et al. (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121: 651-661.
29. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, et al. (2011) Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 6: e16146.
30. Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, et al. (2011) O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 6: e17156.
31. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, et al. (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97: 311-322.
32. Shaw RJ, Akufo-Tetteh EK, Risk JM, Field JK, Liloglou T, (2006) Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res 34: e78.
33. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG, (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280.
34. Kaplan E, Meier P, (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
35. Hothorn T, Lausen B, (2003) On the Exact Distribution of Maximally Selected Rank Statistics. Comput Stat Data Anal 43: 121-137.
36. Schafer J, Strimmer K, (2005) A shrinkage approach to large-scale covariance matrix estimation and implications for functional genomics. Stat Appl Genet Mol Biol 4: Article 32.
37. Gerds TA, Schumacher M, (2007) Efron-type measures of prediction error for survival analysis. Biometrics 63: 1283-1287.
38. R Development Core Team (2011) R: A language and environment for statistical computing. Vienna, Austria.